Patupilone (Epothilone B) for recurrent glioblastoma: Clinical outcome and translational analysis of a single-institution phase I/II trial

Oncology (Switzerland)

Volumn 83, Issue 1, 2012, Pages 1-9

  Oehler, Christoph ^a   Frei, Karl ^a   Rushing, Elisabeth J ^a   McSheehy, Paul M J ^c   Weber, Dirk ^c   Allegrini, Peter R ^c   Weniger, Dorothea ^b   Ltolf, Urs M ^a   Knuth, Alexander ^b   Yonekawa, Yasuhiro ^a   Barath, Krisztina ^b   Broggini Tenzer, Angela ^a   Pruschy, Martin ^a   Hofer, Silvia ^b  

^a Department of Radiation Oncology ^*  (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Epothilone B; Patupilone; Recurrent glioblastoma; Translational research

Indexed keywords

BETA TUBULIN; BETA3 TUBULIN; EPOTHILONE B; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIARRHEA; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TUMOR LEVEL; DRUG WITHDRAWAL; EXECUTIVE FUNCTION; GLIOBLASTOMA; HUMAN; MALE; MENINGITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OVERALL SURVIVAL; PERIOPERATIVE COMPLICATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SENSORY NEUROPATHY; TREATMENT RESPONSE; TUMOR GROWTH;

AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; EPOTHILONES; GLIOBLASTOMA; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; TUBULIN;

EID: 84861994651     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000339152     Document Type: Article

References (35)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996. (Pubitemid 40349501)
2. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17: 2572-2578. (Pubitemid 29368260)
3. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD, North American Brain Tumor Consortium: Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008; 10: 162-170.
4. Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S: Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 2011; 9: 403-407.
5. Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, Marosi C, Ochsenbein A, Pichler J, Roelcke U, Weder P, Zander T, Wick W, Weller M: Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 2011; 50: 630-635.
6. Quant EC, Drappatz J, Wen PY, Norden AD: Recurrent high-grade glioma. Curr Treat Options Neurol 2010; 12: 321-333.
7. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD, Consortium NABT: Is surgery at progression a prognostic marker for improved 6-month progressionfree survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol 2011; 13: 1118-1124.
8. Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS: Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 2004; 100: 41-46. (Pubitemid 38017813)
9. National comprehensive cancer network guidelines, 2011, www.nccn.org.
10. Bystricky B, Chau I: Patupilone in cancer treatment. Expert Opin Investig Drugs 2011; 20: 107-117.
11. Melichar B, Casado E, Bridgewater J, Bennouna J, Campone M, Vitek P, Delord JP, Cerman J, Salazar R, Dvorak J, Sguotti C, Urban P, Viraswami-Appanna K, Tan E, Tabernero J: Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer 2011; 105: 1646-1653.
12. Kavallaris M: Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010; 10: 194-204.
13. O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, Mc-Sheehy PM: Pharmacokinetic profile of the microtubule stabilizer patupilone in tumorbearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol 2008; 62: 1045-1054.
14. Hofstetter B, Vuong V, Broggini-Tenzer A, Bodis S, Ciernik IF, Fabbro D, Wartmann M, Folkers G, Pruschy M: Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin Cancer Res 2005; 11: 1588-1596. (Pubitemid 40315244)
15. Oehler C, von Bueren AO, Furmanova P, Broggini-Tenzer A, Orlowski K, Rutkowski S, Frei K, Grotzer MA, Pruschy M: The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells. Neuro Oncol 2011; 13: 1000-1010.
16. Ferretti S, Becquet M, O'Reilly T, Stumm T, McSheehy P: Patupilone (EPO906) inhibits growth of human NSCLC tumors and subsequent brain metastases and extends survival: comparison with other monotherapies. AACR, 2007, poster 1431.
17. McSheehy P, Allegrini P, Ferretti S, Becquet M, Stumm M: Patupilone, the novel microtubule stabilizer, inhibits growth of intracranial lung tumors in athymic mice. AACR, 2006, poster 545.
18. Bley CR, Jochum W, Orlowski K, Furmanova P, Vuong V, McSheehy PM, Pruschy M: Role of the microenvironment for radiosensitization by patupilone. Clin Cancer Res 2009; 15: 1335-1342.
19. Rohrer Bley C, Orlowski K, Furmanova P, McSheehy PM, Pruschy M: Regulation of VEGF-expression by patupilone and ionizing radiation in lung adenocarcinoma cells. Lung Cancer 2011; 73: 294-301.
20. Bocci G, Nicolaou KC, Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002; 62: 6938-6943. (Pubitemid 35424084)
21. Stalder MW, Anthony CT, Woltering EA: Metronomic dosing enhances the anti-angiogenic effect of epothilone B. J Surg Res 2011; 169: 247-256.
22. Ferretti S, Allegrini PR, O'Reilly T, Schnell C, Stumm M, Wartmann M, Wood J, Mc-Sheehy PM: Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 2005; 11: 7773-7784. (Pubitemid 41611621)
23. O'Reilly T, Wartmann M, Maira SM, Hattenberger M, Vaxelaire J, Muller M, Ferretti S, Buchdunger E, Altmann KH, McSheehy PM: Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemother Pharmacol 2005; 55: 307-317. (Pubitemid 40379253)
24. Fogh S, Machtay M, Werner-Wasik M, Curran WJ, Bonanni R, Axelrod R, Andrews D, Dicker AP: Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2010; 77: 1009-1016.
25. Weniger D: Aphasia. Stuttgart, Thieme, 2006.
26. Blum W, Aichholz R, Ramstein P, Kühnöl J, Brüggen J, O'Reilly T, Flörsheimer A: In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary highpressure liquid chromatography/mass spectrometry/ tandem mass spectrometry. Rapid Commun Mass Spectrom 2001;15:41-49. (Pubitemid 32094790)
27. Rowley HA, Roberts TP: Clinical perspectives in perfusion: neuroradiologic applications. Top Magn Reson Imaging 2004; 15: 28-40. (Pubitemid 38437543)
28. Hofer S, Frei K, Rutz HP: Gefitinib accumulation in glioblastoma tissue. Cancer Biol Ther 2006; 5: 483-484. (Pubitemid 43765281)
29. Hofer S, Frei K: Gefitinib concentrations in human glioblastoma tissue. J Neurooncol 2007; 82: 175-176. (Pubitemid 46431861)
30. Stupp R, Tosoni A, Bromberg JE, Hau P, Campone M, Gijtenbeek J, Frenay M, Breimer L, Wiesinger H, Allgeier A, van den Bent MJ, Bogdahn U, van der Graaf W, Yun HJ, Gorlia T, Lacombe D, Brandes AA: Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol 2011; 22: 2144-2149.
31. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY: Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2011; 29: 2689-2695.
32. Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS: Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 2011; 101: 57-66.
33. Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A, Nikolova Z: Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 2009; 101: 1995-2004.
34. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK: Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28: 2817-2823.
35. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS: Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 2010; 12: 508-516.